Mylan Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mylan Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
Mylan Pharmaceuticals: 146 sponsored US clinical trials, 1 recruiting.
Mylan Pharmaceuticals sponsors 146 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 143 completed. 3 of these trials are in Phase 3-4 (later-stage) and 143 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 35 trials.
Top-decile sponsor footprint
Mylan Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 3 of 3
Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg
NCT00649194
Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day
NCT00649896
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
NCT00649532
Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
NCT00648583
Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
NCT00648921
Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
NCT00647777
Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg
NCT00649493
Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg
NCT00648349
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg
NCT00647855
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
NCT00647972
Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg
NCT00649012
Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg
NCT00649558
Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg
NCT00649688
Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg
NCT00648778
Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg
NCT00648024
Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg
NCT00649233
Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg
NCT00648557
Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg
NCT00648765
Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System
NCT00650442
Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
NCT00648856
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
NCT00649116
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg
NCT00648271
Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
NCT00650481
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
NCT00649038
Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg
NCT00649649
Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg
NCT00649103
Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg
NCT00649051
Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
NCT00648843
Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg
NCT00650065
Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg
NCT00649857
Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
NCT00649597
Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
NCT00650325
Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg
NCT00649285
Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg
NCT00648492
Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg
NCT00650312
Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
NCT00649259
Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
NCT00648440
Fasting Study of Modafinil Tablets 200 mg and Provigil® Tablets 200 mg
NCT00650000
Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg
NCT00650286
Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
NCT00650364
Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg
NCT00649727
Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
NCT00649129
Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)
NCT01012934
Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
NCT00650013
Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg
NCT01018342
Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)
NCT00983996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Mylan Pharmaceuticals pipeline
1 recruiting of 146 indexed (1% open); 143 completed (98%).
Phase mix: 3 late (III/IV) vs 143 early (I/II) (early-phase heavy).
Top condition: Healthy (35 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mylan Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 146 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Mylan Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- HealthPartners Institute · 146 trials · 8% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Shire · 0% recruiting · 245 trials
- Abbott Nutrition · 1% recruiting · 89 trials
Related
What to do with this Mylan Pharmaceuticals page
146 registered trials is a research-attention snapshot, not an endorsement of Mylan Pharmaceuticals or any single study.
- 1 of Mylan Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Mylan Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mylan Pharmaceuticals pipeline card: 146 registered trials from official public datasets.Report a data error.